



# UNIVERSITY of MARYLAND SCHOOL OF MEDICINE

 [Update Your Profile](#)

## Julie A. Kreyenbuhl, PharmD, PhD

Academic Title:

Associate Professor

Primary Appointment:

Psychiatry

Email:

[jkrevenb@psych.umaryland.edu](mailto:jkrevenb@psych.umaryland.edu)

Location:

VA Annex, 735

Phone (Primary):

410-637-1864

Phone (Secondary):

410-706-3211

Fax:

410-637-1880

[Download CV](#)

## Education and Training

Dr. Kreyenbuhl received a Pharm.D. from Mercer University College of Pharmacy and Health Sciences in 1993 and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy in 1999. She completed a post-doctoral fellowship at the Maryland Psychiatric Research Center in 2000.

## Biosketch

Dr. Kreyenbuhl's primary research interest is the pharmacoepidemiology of serious mental illness. She has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. In addition, Dr. Kreyenbuhl has

expertise in the area of medication adherence and has received support from the Brain and Behavior Research Foundation to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for metabolic side effects increases rates of screening and activates patients to discuss screening with their providers. She has also received grant funding from VA HSR&D to study how women Veterans with serious mental illnesses and their prescribers manage the metabolic side effects of psychotropic medications of which women are disproportionately affected. She is also the PI, Co-PI, or co-investigator on other funded efforts to study computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 80 publications in peer-reviewed journals.

## Research/Clinical Keywords

serious mental illness; health services research; pharmacoepidemiology

## Highlighted Publications

Kreyenbuhl J, Record EJ, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon LB, Medoff DR, Li L. Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications. *Clinical Schizophrenia & Related Psychoses* 2016 Jul 25. [Epub ahead of print] PubMed PMID: 27454213.

Kreyenbuhl J, Dixon LB, Brown CH, Medoff DR, Klingaman EA, Fang L, Tapscott S, Walsh M. A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. *Community Mental Health Journal* 2016 Apr 9. [Epub ahead of print] PubMed PMID: 27061185.

Kreyenbuhl J, Medoff DR, McEvoy JP, Smith TE, Hackman A, Nossel IR, Dixon LB, Essock SM, Buchanan RW. The RAISE Connection Program: Psychopharmacological Treatment of People with a First Episode of Schizophrenia. *Psychiatric Services*; 2016 Jul 1:appips201500438. [Epub ahead of print] PubMed PMID: 27364816.

Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of Behavioral Tailoring Strategies for Improving Medication Adherence in Serious Mental Illness. *Dialogues in Clinical Neuroscience* 2016 Jun;18(2):191-201.

Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. *Schizophr Bull* 2010 Jan; 36(1):94-103.

 [Update Your Profile](#)